Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PMA Slowdown To Persist In ’04, McClellan Says; User Fee Hikes To Follow?

This article was originally published in The Gray Sheet

Executive Summary

FDA expects the rate of new product applications to continue declining for the foreseeable future, despite a series of review cycle improvement initiatives begun in January

You may also be interested in...



OMB Likely Will Pledge 2005 User Fee Funds; Dec. 3 Is Round Two For MDMA

A third-party audit of FDA review costs and workload data associated with the Medical Device User Fee & Modernization Act may be in the offing

OMB Program Assessment Tool Benefits Medical Device Review Reduction

FDA's revised target for medical device review times would yield a nearly 10% reduction in total FDA days for half the premarket applications approved between fiscal 2005 and 2007

User Fees Hiked In FY ’04: Fewer Submissions, Bundling Cited As Factors

PMA submission trends over the next 12 months will help determine whether device user fees in fiscal 2005 continue to rise at the FY 2004 rate

Related Content

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel